Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome?

Tellenbach, Marc; Schneider, Marc Philipp; Mordasini, Livio; Thalmann, George N.; Kessler, Thomas M. (2013). Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome? World journal of urology, 31(5), pp. 1205-1210. Springer Berlin Heidelberg 10.1007/s00345-012-0888-z

[img] Text
Tellenbach_World J Urol_2013_31_1205.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (243kB) | Request a copy
[img]
Preview
Text
345_2012_Article_888.pdf - Other
Available under License Publisher holds Copyright.

Download (243kB) | Preview

PURPOSE: To assess the effect of transcutaneous electrical nerve stimulation (TENS) for treating refractory overactive bladder syndrome (OAB). PATIENTS AND METHODS: A consecutive series of 42 patients treated with TENS for refractory OAB was prospectively investigated at an academic tertiary referral centre. Effects were evaluated using bladder diary for at least 48 h and satisfaction assessment at baseline, after 12 weeks of TENS treatment, and at the last known follow-up. Adverse events related to TENS were also assessed. RESULTS: Mean age of the 42 patients (25 women, 17 men) was 48 years (range, 18-76). TENS was successful following 12 weeks of treatment in 21 (50 %) patients, and the positive effect was sustained during a mean follow-up of 21 months (range, 6-83 months) in 18 patients. Following 12 weeks of TENS treatment, mean number of voids per 24 h decreased significantly from 15 to 11 (p < 0.001) and mean voided volume increased significantly from 160 to 230 mL (p < 0.001). In addition, TENS completely restored continence in 7 (39 %) of the 18 incontinent patients. Before TENS, all 42 patients were dissatisfied or very dissatisfied; following 12 weeks of TENS treatment, 21 (50 %) patients felt satisfied or very satisfied (p < 0.001). No adverse events related to TENS were noted. CONCLUSIONS: TENS seems to be an effective and safe treatment for refractory OAB warranting randomized, placebo-controlled trials.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > University Emergency Center
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Tellenbach, Marc; Mordasini, Livio Marco; Thalmann, George and Kessler, Thomas M.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0724-4983

Publisher:

Springer Berlin Heidelberg

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

04 Jun 2014 09:02

Last Modified:

01 Oct 2018 02:30

Publisher DOI:

10.1007/s00345-012-0888-z

PubMed ID:

22622396

BORIS DOI:

10.7892/boris.43746

URI:

https://boris.unibe.ch/id/eprint/43746 (FactScience: 222774)

Actions (login required)

Edit item Edit item
Provide Feedback